All patients
Age < 65y (younger) Age > 65y Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male PDL1 < 25% PDL1 >25% smoker (current or former) smoker (never) stage IIIa stage IIIb
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
laNSCLC - M - all population, durvalumab alone vs. non active control, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results PACIFIC, 2017 0.68 [0.47; 0.99]
0.68 [0.47 ; 0.99 ] PACIFIC, 2017 1 0% 713 NA not evaluable deaths (OS) (extension)detailed results PACIFIC, 2017 0.72 [0.59; 0.88]
0.72 [0.59 ; 0.88 ] PACIFIC, 2017 1 0% 713 NA not evaluable PFS (extension)detailed results PACIFIC, 2017 0.55 [0.45; 0.68]
0.55 [0.45 ; 0.68 ] PACIFIC, 2017 1 0% 713 NA not evaluable progression or deaths (PFS)detailed results PACIFIC, 2017 0.52 [0.42; 0.65]
0.52 [0.42 ; 0.65 ] PACIFIC, 2017 1 0% 713 NA not evaluable objective responses (ORR)detailed results PACIFIC, 2017 2.03 [1.36; 3.03]
2.03 [1.36 ; 3.03 ] PACIFIC, 2017 1 0% 713 NA not evaluable AE (any grade)detailed results PACIFIC, 2017 1.66 [0.76; 3.60]
1.66 [0.76 ; 3.60 ] PACIFIC, 2017 1 0% 709 NA not evaluable AE (grade 3-4)detailed results PACIFIC, 2017 1.21 [0.85; 1.72]
1.21 [0.85 ; 1.72 ] PACIFIC, 2017 1 0% 709 NA not evaluable AE leading to death (grade 5)detailed results PACIFIC, 2017 0.79 [0.39; 1.60]
0.79 [0.39 ; 1.60 ] PACIFIC, 2017 1 0% 709 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results PACIFIC, 2017 1.67 [1.01; 2.74]
1.67 [1.01 ; 2.74 ] PACIFIC, 2017 1 0% 709 NA not evaluable SAE (any grade)detailed results PACIFIC, 2017 1.37 [0.95; 1.97]
1.37 [0.95 ; 1.97 ] PACIFIC, 2017 1 0% 709 NA not evaluable TRAE (any grade)detailed results PACIFIC, 2017 1.84 [1.33; 2.53]
1.84 [1.33 ; 2.53 ] PACIFIC, 2017 1 0% 709 NA not evaluable TRAE (grade 3-4)detailed results PACIFIC, 2017 2.99 [1.50; 5.98]
2.99 [1.50 ; 5.98 ] PACIFIC, 2017 1 0% 709 NA not evaluable TRAE leading to death (grade 5)detailed results PACIFIC, 2017 1.15 [0.30; 4.49]
1.15 [0.30 ; 4.49 ] PACIFIC, 2017 1 0% 709 NA not evaluable Asthenia TRAE (grade 3-4)detailed results PACIFIC, 2017 2.97 [0.15; 59.50]
2.97 [0.15 ; 59.50 ] PACIFIC, 2017 1 0% 709 NA not evaluable Cough TRAE (grade 3-4)detailed results PACIFIC, 2017 0.49 [0.01; 24.88]
0.49 [0.01 ; 24.88 ] PACIFIC, 2017 1 0% 709 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results PACIFIC, 2017 0.25 [0.01; 7.35]
0.25 [0.01 ; 7.35 ] PACIFIC, 2017 1 0% 709 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results PACIFIC, 2017 0.49 [0.07; 3.50]
0.49 [0.07 ; 3.50 ] PACIFIC, 2017 1 0% 709 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results PACIFIC, 2017 2.97 [0.15; 59.50]
2.97 [0.15 ; 59.50 ] PACIFIC, 2017 1 0% 709 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results PACIFIC, 2017 0.49 [0.01; 24.88]
0.49 [0.01 ; 24.88 ] PACIFIC, 2017 1 0% 709 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results PACIFIC, 2017 0.99 [0.03; 29.48]
0.99 [0.03 ; 29.48 ] PACIFIC, 2017 1 0% 709 NA not evaluable Nausea TRAE (grade 3-4)detailed results PACIFIC, 2017 0.49 [0.01; 24.88]
0.49 [0.01 ; 24.88 ] PACIFIC, 2017 1 0% 709 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results PACIFIC, 2017 0.65 [0.22; 1.90]
0.65 [0.22 ; 1.90 ] PACIFIC, 2017 1 0% 709 NA not evaluable Pruritus TRAE (grade 3-4)detailed results PACIFIC, 2017 0.49 [0.01; 24.88]
0.49 [0.01 ; 24.88 ] PACIFIC, 2017 1 0% 709 NA not evaluable Rash TRAE (grade 3-4)detailed results PACIFIC, 2017 0.99 [0.03; 29.48]
0.99 [0.03 ; 29.48 ] PACIFIC, 2017 1 0% 709 NA not evaluable Anaemia AE (grade 3-4)detailed results PACIFIC, 2017 0.86 [0.35; 2.07]
0.86 [0.35 ; 2.07 ] PACIFIC, 2017 1 0% 709 NA not evaluable Arthralgia AE (grade 3-4)detailed results PACIFIC, 2017 0.49 [0.01; 24.88]
0.49 [0.01 ; 24.88 ] PACIFIC, 2017 1 0% 709 NA not evaluable Asthenia AE (grade 3-4)detailed results PACIFIC, 2017 1.48 [0.15; 14.32]
1.48 [0.15 ; 14.32 ] PACIFIC, 2017 1 0% 709 NA not evaluable Back pain AE (grade 3-4)detailed results PACIFIC, 2017 0.49 [0.03; 7.89]
0.49 [0.03 ; 7.89 ] PACIFIC, 2017 1 0% 709 NA not evaluable Constipation AE (grade 3-4)detailed results PACIFIC, 2017 0.99 [0.03; 29.48]
0.99 [0.03 ; 29.48 ] PACIFIC, 2017 1 0% 709 NA not evaluable Cough AE (grade 3-4)detailed results PACIFIC, 2017 0.99 [0.09; 10.92]
0.99 [0.09 ; 10.92 ] PACIFIC, 2017 1 0% 709 NA not evaluable Decreased appetite AE (grade 3-4)detailed results PACIFIC, 2017 0.24 [0.02; 2.71]
0.24 [0.02 ; 2.71 ] PACIFIC, 2017 1 0% 709 NA not evaluable Diarrhoea AE (grade 3-4)detailed results PACIFIC, 2017 0.49 [0.10; 2.44]
0.49 [0.10 ; 2.44 ] PACIFIC, 2017 1 0% 709 NA not evaluable Dyspnoea AE (grade 3-4)detailed results PACIFIC, 2017 0.57 [0.19; 1.71]
0.57 [0.19 ; 1.71 ] PACIFIC, 2017 1 0% 709 NA not evaluable Fatigue AE (grade 3-4)detailed results PACIFIC, 2017 0.16 [0.02; 1.57]
0.16 [0.02 ; 1.57 ] PACIFIC, 2017 1 0% 709 NA not evaluable Headache AE (grade 3-4)detailed results PACIFIC, 2017 0.24 [0.02; 2.71]
0.24 [0.02 ; 2.71 ] PACIFIC, 2017 1 0% 709 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results PACIFIC, 2017 0.99 [0.03; 29.48]
0.99 [0.03 ; 29.48 ] PACIFIC, 2017 1 0% 709 NA not evaluable Nausea AE (grade 3-4)detailed results PACIFIC, 2017 0.49 [0.01; 24.88]
0.49 [0.01 ; 24.88 ] PACIFIC, 2017 1 0% 709 NA not evaluable Pneumonia AE (grade 3-4)detailed results PACIFIC, 2017 1.16 [0.52; 2.57]
1.16 [0.52 ; 2.57 ] PACIFIC, 2017 1 0% 709 NA not evaluable Pneumonitis AE (grade 3-4)detailed results PACIFIC, 2017 1.32 [0.51; 3.43]
1.32 [0.51 ; 3.43 ] PACIFIC, 2017 1 0% 709 NA not evaluable Pruritus AE (grade 3-4)detailed results PACIFIC, 2017 0.49 [0.01; 24.88]
0.49 [0.01 ; 24.88 ] PACIFIC, 2017 1 0% 709 NA not evaluable Pyrexia AE (grade 3-4)detailed results PACIFIC, 2017 0.99 [0.03; 29.48]
0.99 [0.03 ; 29.48 ] PACIFIC, 2017 1 0% 709 NA not evaluable Rash AE (grade 3-4)detailed results PACIFIC, 2017 0.99 [0.03; 29.48]
0.99 [0.03 ; 29.48 ] PACIFIC, 2017 1 0% 709 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 00:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 195
- treatments: 374